An expert at ESMO 2026 explains how liquid biopsy and ESR1 testing can help guide treatment for people with HR-positive metastatic breast cancer.
|Videos|August 12, 2016
The Surprising Benefit of Soybean Oil for Patients With Breast Cancer
Author(s)Luke Peppone
Luke Peppone, assistant professor at the University of Rochester Medical Center, discusses the surprising benefits soybean oil had for patients with breast cancer.
Advertisement
Luke Peppone, assistant professor at the University of Rochester Medical Center, discusses the surprising benefits soybean oil had for patients with breast cancer.
In a small feasibility study, researchers at University of Rochester Medical Center were exploring what dose of omega-3 would be best for reducing fatigue in patients with breast cancer. What they found, however, was that the patients in the control group who were given soybean oil, which is high in omega-6, actually saw the most significant decrease in fatigue.
Advertisement
Related to this article
After breast cancer at 30, Aisha shares her journey through motherhood, a double mastectomy, body image struggles and the challenges of survivorship.
Dr. Saum Ghodoussipour of Rutgers Cancer Institute answers top searched bladder cancer questions, from treatment and surgery side effects to sex and work.
Joy Maulik, MSN, FNP-C, explains why a prostate cancer diagnosis should be seen as a change in direction, not an ending, and how patients can lean on education, their providers and caregivers.
Dr. Morana Vojnic answers common questions about brain cancer, including diagnosis, tumor types, treatment effects, recurrence and life after treatment begins.
Longer follow-up presented at the 2026 ESMO Congress showed that four already-approved treatments for early breast cancer, kidney cancer, colorectal cancer and stomach and esophageal cancer kept helping patients years later.
Dr. Jacqueline Barrientos shares how a targeted therapy, a determined care team and a stranger’s generosity gave a 72-year-old man with hairy cell leukemia and kidney failure a second chance.
Two phase 3 trials at ESMO 2026 brought new options for advanced endometrial cancer, and final results for Verzenio after another CDK4/6 drug showed a survival difference that was not statistically significant.
Advertisement
Advertisement
Trending on CURE
1
Medicare to Cut Ostomy Suppliers to 6 Contracts: What Patients Need to Know
2
3 Prostate Cancer Results From ESMO 2026 Patients Should Know
3
4 Long-Term Survival Results From ESMO 2026 Patients Should Know
4
CAR T-Cell Therapy Offers Hope for Lasting Remission in Hairy Cell Leukemia
5